These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 28381431)

  • 1. Molecular biomarkers for lung adenocarcinoma.
    Calvayrac O; Pradines A; Pons E; Mazières J; Guibert N
    Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28381431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
    Ou SH
    J Clin Pathol; 2013 Oct; 66(10):839-46. PubMed ID: 23661716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
    Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
    Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis.
    Sholl LM
    Semin Diagn Pathol; 2015 Sep; 32(5):325-33. PubMed ID: 25753527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances on driver oncogenes of lung adenocarcinoma].
    Wang J; Zhang Z; Zhang S
    Zhongguo Fei Ai Za Zhi; 2013 Feb; 16(2):91-6. PubMed ID: 23425901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.
    Oshita F; Kasajima R; Miyagi Y
    J Exp Ther Oncol; 2016 Jul; 11(3):189-194. PubMed ID: 28471124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
    Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
    Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to "MiR-205 and miR-375 microRNA Assays to Distinguish Squamous Cell Carcinoma From Adenocarcinoma in Lung Cancer Biopsies".
    Patnaik SK; Yendamuri S; Mallick R; Dhillon SS
    J Thorac Oncol; 2015 Jun; 10(6):e53. PubMed ID: 26001155
    [No Abstract]   [Full Text] [Related]  

  • 11. MicroRNA Assays for Diagnosis Lung Cancer Biopsy.
    Wiwanitkit V
    J Thorac Oncol; 2015 Jun; 10(6):e52-3. PubMed ID: 26001154
    [No Abstract]   [Full Text] [Related]  

  • 12. Section IV: non-small cell lung cancer and malignant melanoma.
    Fisher KE; Pillai RN; Kudchadkar RR; Rossi MR
    Curr Probl Cancer; 2014; 38(5):180-98. PubMed ID: 25281457
    [No Abstract]   [Full Text] [Related]  

  • 13. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
    Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
    Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Driver Mutations Detected in NSCLC.
    Cancer Discov; 2016 Aug; 6(8):809. PubMed ID: 27297549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
    JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
    [No Abstract]   [Full Text] [Related]  

  • 16. Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.
    Bernicker EH; Miller RA; Cagle PT
    J Oncol Pract; 2017 Apr; 13(4):221-227. PubMed ID: 28399384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances on driver oncogenes of non-small cell lung cancer].
    Zhao J; Xiong J
    Zhongguo Fei Ai Za Zhi; 2015 Jan; 18(1):42-7. PubMed ID: 25603872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for NSCLC with driver mutations.
    Minuti G; D'Incecco A; Cappuzzo F
    Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung carcinoma progression and survival versus amino- and carboxyl-parathyroid hormone-related protein expression.
    Hastings RH; Montgrain PR; Quintana RA; Chobrutskiy B; Davani A; Miyanohara A; Mahooti S
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1395-1407. PubMed ID: 28342003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.